Prajwal Chevireddy, MD
Nephrology · Little Rock, ARNPI 1255543278
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,160 of the $3,363 with a category attached, or 64.2%. Amgen accounts for 68.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $2,160 and has fallen 89.2% since, to $233 in 2025.
Across 32 payments — averaging $105.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Ardelyx, Inc.$180
- Otsuka America Pharmaceutical, Inc.$128
- Gilead$125
- Vantive US Healthcare LLC$121
- Mallinckrodt Enterprises LLC$105
- plus $400 from 7 others
What the payments were for
- Speaking & faculty fees$2,16064%
- Food & beverage$96429%
- Education$2397%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 3 | $2,304 |
| Ardelyx, Inc. | 2 | $180 |
| Otsuka America Pharmaceutical, Inc. | 4 | $128 |
| Gilead | 1 | $125 |
| Vantive US Healthcare LLC | 1 | $121 |
| Mallinckrodt Enterprises LLC | 1 | $105 |
| Travere Therapeutics, Inc. | 11 | $97 |
| Fresenius USA Marketing, Inc. | 4 | $91 |
| AstraZeneca | 1 | $86 |
| GSK | 1 | $73 |
| Novo Nordisk | 1 | $20 |
| Bayer | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$2,284
- Biktarvy$125
- Renal - PD$121
- XPHOZAH 30 MG$120
- ACTHAR$105
How this compares
$3,363 in reported general payments places this provider in the 70th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 229 | $169,624 |
| VelphoroSucroferric Oxyhydroxide | 68 | $167,081 |
| Sevelamer Carbonate | 193 | $26,057 |
| JardianceEmpagliflozin | 31 | $24,673 |
| Calcitriol | 732 | $13,369 |
| XareltoRivaroxaban | 12 | $7,486 |
| Paricalcitol | 30 | $2,586 |
| Potassium Chloride | 93 | $2,270 |
| Nifedipine ErNifedipine | 102 | $1,513 |
| Cinacalcet Hcl | 20 | $1,468 |
| Hydralazine Hcl | 99 | $1,293 |
| Amlodipine Besylate | 239 | $1,153 |
| Febuxostat | 22 | $1,136 |
| Losartan Potassium | 179 | $1,127 |
| Tamsulosin Hcl | 102 | $1,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $86 | $169,624229 claims |
| Fresenius USA Marketing, Inc.Velphoro | $91 | $167,08168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 85 nephrology providers in Arkansas.
Other nephrology in Little Rock
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- John ArthurLittle Rock$7K
- Moses EjioforLittle Rock$6K
- Alex DavidLittle Rock$6K
- Muhammad AlamLittle Rock$2K
- Kashaf RasheedLittle Rock$2K
- Fakhar IjazLittle Rock$2K
- Nithin KarakalaLittle Rock$739
- Garry GlascoLittle Rock$459
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.